Novartis gives New York its layoff plans for Suffern; Poor-quality Indian generics go to Africa;

@FiercePharma: Now trending on FiercePharmaMarketing: First-to-market launch? Bonus--but double bonus if you're Big Pharma. Article | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. More | Follow @EricPFierce

@CarlyHFierce: This week in FiercePharmaMarketing: Takeda lets 900 reps fly at obesity; AZ + James Van Der Beek = FluMist sales? More | Follow @CarlyHFierce

> Novartis ($NVS) has mapped out for the state of New York how it will lay off its workers prior to a 2016 facility closure in Suffern. More

> Generic drugs that some Indian companies send to African countries are lower quality than the same medicines the companies sell at home and outside the African continent, a study has found. Report

> The U.K.'s drug cost watchdog is calling for a review of the way in which new drugs are adopted, evaluated and taken up by the Britain's National Health Service. More

> As it gears up to launch Duchenne muscular dystrophy treatment Translarna in the EU, PTC Therapeutics is adding execs to its global commercial team. Release

> Cipla has granted Salix Pharmaceuticals ($SLXP) exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family it controls. Release

Medical Device News

@FierceMedDev: Researchers develop the first blood test to diagnose adult depression. Story | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of polio vax application. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Drug delivery specialist Genisphere receives an additional $2M in funding. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Mainstay Medical CEO reveals company's path to market for its neuromodulation implant. More | Follow @EmilyWFierce

> Intrinsic raising $21M for implant to improve lumbar disc surgery. Story

> 23andMe customers must now opt in to find unknown close relatives via genetic test. More

> Mainstay Medical bucks M&A trend, sets own course for neuromodulation. News

Biotech News

@FierceBiotech: Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac. News | Follow @FierceBiotech

@JohnCFierce: Am I missing something? If the FDA eviscerates the low-T market, restricting use, doesn't that destroy the prospects of , Clarus, etc.? | Follow @JohnCFierce

@DamianFierce: $NVO's eye on a Seattle expansion could be balm to local biotech as Amgen heads for the door. Article | Follow @DamianFierce

@EmilyMFierce: ICYMI: Check out these 7 notable academic-pharma alliances of 2014. Feature | Follow @EmilyMFierce

> Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1. Story

> Merck's weekly diabetes drug stacks up to blockbuster Januvia in Phase III. Report

> Oral low-T drugs in the pipeline face a showdown with the FDA. More

Vaccines News

> Takeda reorg preps vaccines unit for emerging markets test. News

> 10 volunteers receive Glaxo Ebola vaccine with no adverse effects yet. Story

> Merck KGaA calls it quits on cancer vaccine--again. More

> Protein Sciences nabs stake in diabetes vax developer Diamyd. Story

> AstraZeneca sends James Van Der Beek 'camping' to promote FluMist Quadrivalent. Article

Pharma Manufacturing News

> More FDA issues arise for Hospira in India. News

> Novartis says more cuts coming for New York Diovan plant. More

> FDA procedural delay on Rytary gives Impax breathing room. Report

> Baxter issues recall, this time because antibacterial gets mixed in wrong carton. Story

> Partner Sanofi wants to produce the insulin to be used in MannKind's Afrezza. Article

And Finally... Research shows zero-calorie sweeteners can raise your blood sugar. More (sub. req.)

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.